Company Profile
Iovance Biotherapeutics, Inc. Stock Price, News & Analysis
- Ticker:
- IOVA
- Exchange:
- NASDAQ
- Sector:
- Biotechnology
- Location:
- United States
Stock performance
4.04 USD (-4.49%)
Close
Last updated: July 13, 2026 at 00:00
1.89B USD
Market cap
Why the stock is moving
IOVA is trading as a commercial-stage cell therapy name with investors focused on launch execution, adoption, and the next catalyst window. The market usually reprices the stock quickly when TIL therapy progress, regulatory updates, or revenue signals shift the story.
Company overview
Business overview
Iovance Biotherapeutics is a commercial-stage cell therapy company focused on tumor-infiltrating lymphocyte, or TIL, therapies for solid tumors. The company's story is centered on turning a complex personalized treatment approach into a scalable oncology franchise, with investors watching launch execution, adoption, and the broader expansion of the TIL platform.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Iovance Biotherapeutics is classified within biopharmaceuticals. The company is followed for its exposure to oncology and cell therapy, two areas where clinical execution and regulatory momentum can quickly reshape the investment case.
Business Model Characteristics
Iovance's model combines commercial rollout with pipeline development. Near term, the market focuses on real-world adoption, treatment access, and the pace of revenue buildout. Longer term, attention shifts to label expansion, additional tumor settings, and whether the company can broaden TIL therapy beyond its initial launch markets.
Position Within the Biotechnology Landscape
Iovance sits in the high-catalyst end of the biotechnology landscape, where cell therapy names are often valued on clinical execution, manufacturing readiness, and the ability to convert scientific promise into commercial traction. Compared with larger, more diversified biotech peers, the stock tends to react more sharply to trial updates, regulatory progress, and launch milestones.
Future catalysts
Over the next three months, the stock is likely to react to earnings, conference commentary, and regulatory follow-through tied to the TIL platform or existing launch markets.
The next earnings call should be the first major checkpoint because it can update revenue trends, margin signals, and management's view on commercialization and pipeline priorities.
Conference season also matters. Scientific and investor meetings can surface new data points, launch details, and commentary on cell therapy adoption before the wider market fully reprices them.
Regulatory milestones and label updates remain the main optionality layer. Any FDA decision or supplemental filing can quickly change the narrative around the newest approved or late-stage assets.
Recent news
The five most recent related feed items are shown below in reverse chronological order.
- 01
Zimmer Biomet Names Chintan Desai President of Asia Pacific Region
ZBH · Source: Zimmer Biomet
- 02
Zimmer Biomet Announces Webcast and Conference Call of Second Quarter 2026 Financial Results
ZBH · Source: Zimmer Biomet
- 03
U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma
BMY · Source: BMYBristol-Myers Squibb Company
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Iovance Biotherapeutics, Inc. (IOVA)?
Iovance Biotherapeutics, Inc. (IOVA) most recently closed at 4.04 USD, a -4.49% move versus the previous session.
What is the market cap of Iovance Biotherapeutics, Inc. (IOVA)?
Iovance Biotherapeutics, Inc. currently has a market capitalization of 1.89B USD on BioPharmSignal.
What does Iovance Biotherapeutics, Inc. do?
Iovance Biotherapeutics is a commercial-stage cell therapy company focused on tumor-infiltrating lymphocyte, or TIL, therapies for solid tumors. The company's story is centered on turning a complex personalized treatment approach into a scalable oncology franchise, with investors watching launch execution, adoption, and the broader expansion of the TIL...
On which exchange is IOVA stock listed?
Iovance Biotherapeutics, Inc. (IOVA) is associated with NASDAQ, United States, Biotechnology.
What is Iovance?
Iovance Biotherapeutics is a commercial-stage cell therapy company focused on tumor-infiltrating lymphocyte, or TIL, therapies for solid tumors.
Which conditions is Iovance Biotherapeutics, Inc. targeting with Iovance?
Iovance Biotherapeutics, Inc. is associated with oncology based on its company overview and current catalyst commentary.
How does Iovance Biotherapeutics, Inc. describe recent progress with Iovance?
Over the next three months, the stock is likely to react to earnings, conference commentary, and regulatory follow-through tied to the TIL platform or existing launch markets. The next earnings call should be the first major checkpoint because it can update revenue trends, margin signals, and management's view on commercialization and pipeline priorities....
What is Biotherapeutics?
Iovance Biotherapeutics is a commercial-stage cell therapy company focused on tumor-infiltrating lymphocyte, or TIL, therapies for solid tumors.